Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 May;11(5):277-86.
doi: 10.1007/BF02598268.

Physician extenders for cost-effective management of hypercholesterolemia

Affiliations
Clinical Trial

Physician extenders for cost-effective management of hypercholesterolemia

G Schectman et al. J Gen Intern Med. 1996 May.

Abstract

Objective: Treatment of elevated cholesterol levels reduces morbidity and mortality from coronary heart disease in high-risk patients, but can be costly. The purpose of this study was to determine whether physician extenders emphasizing diet modification and, when necessary, effective and inexpensive drug algorithms can provide more cost-effective therapy than conventional care.

Design: Randomized controlled trial.

Setting: A Department of Veterans Affairs Medical Center.

Patients: Two hundred forty-seven veterans with type IIa hypercholesterolemia.

Interventions: Patients assigned to either a cholesterol treatment program (CTP) or usual health care provided by general internists (UHC). CTP included intensive dietary therapy administered by a registered dietitian utilizing individual and group counseling and drug therapy initiated by physician extenders for those failing to achieve goal low-density lipoprotein (LDL) levels with diet alone. A drug selection algorithm for CTP subjects utilized niacin as initial therapy followed by bile acid sequestrants and lovastatin. Subjects were followed prospectively for 2 years.

Measurements: Primary outcome measurements were effectiveness of therapy defined as reductions in LDL cholesterol (LDL-C), and whether goal LDL-C levels were achieved; costs of therapy; and cost-effectiveness defined as the cost per unit reduction in the LDL-C.

Main results: Total program costs were higher for CTP patients than for UHC patients ($659 +/- $43 vs $477 +/- $42 per patient, p < .001). However, at 24 months the patients in CTP were more likely to achieve LDL goal levels (65% vs 44%, p < .005), and also achieved greater reductions in LDL-C 27% +/- 2% vs 14% +/- 2% at 24 months, p < .001). Program costs per unit (mmol/L) reduction in the LDL-C, a measure of cost-effectiveness, was significantly lower for CTP ($758 +/- $58 vs $1,058 +/- $70, p = .002).

Conclusions: Although more expensive than usual care, the greater effectiveness of physician extenders implementing cholesterol treatment algorithms resulted in more cost-effective therapy.

PubMed Disclaimer

Comment in

  • ACP J Club. 1996 Nov-Dec;125(3):80-1

References

    1. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
    1. Circulation. 1992 Apr;85(4):1293-303 - PubMed
    1. JAMA. 1993 Jun 16;269(23):3015-23 - PubMed
    1. Public Health Rep. 1992 Jul-Aug;107(4):441-8 - PubMed
    1. Am J Cardiol. 1993 Apr 1;71(10):759-65 - PubMed

Publication types

LinkOut - more resources